Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Development candidates in pipeline (candidates): 25.00 candidates in FY2025, down 26.5% from a year earlier.
Latest, FY2025
25.00
Period ended Dec 31, 2025
Change on a year earlier
-26.5%
34.00 in FY2024
History
8 years
Since FY2018
Sources
7
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Note 1 & MD&A Overview.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development candidates in pipeline (candidates) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.00 | -26.5% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 34.00 | -19.0% | Form 10-K (filed 2025-02-21) ↗ |
| FY2023 | Dec 31, 2023 | 42.00 | -6.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 45.00 | +21.6% | FY2024 10-K ↗ |
| FY2021 | Dec 31, 2021 | 37.00 | +76.2% | FY2021 10-K ↗ |
| FY2020 | Dec 31, 2020 | 21.00 | -12.5% | FY2021 10-K ↗ |
| FY2019 | Dec 31, 2019 | 24.00 | +14.3% | FY2019 10-K ↗ |
| FY2018 | Dec 31, 2018 | 21.00 | – | FY2018 10-K ↗ |
Cite this data
StockData. (2026). Moderna Development candidates in pipeline (candidates), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/pipeline-candidates
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.